Jeito Capital, a global independent Private Equity fund with a focus on biopharma, has announced that it is leading a USD 65 million financing round in ReproNovo. The company is dedicated to developing innovative treatments for reproductive medicine and women’s health. The funding will advance ReproNovo’s lead candidates RPN-001 and RPN-002 through Phase 2 clinical trials in male infertility and in the treatment of adenomyosis and embryo implantation, respectively. This investment highlights Jeito’s interest in highly promising clinical-stage biopharma companies developing breakthrough innovations with strong value-creation potential for patients and society in the context of increasing worldwide infertility. ReproNovo is developing novel approaches to address critical gaps in reproductive medicine and women’s health, including male and female infertility and uterine health.